CLINICAL STUDY: MANAGEMENT OF HYPERCHOLESTEROLEMIA
Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy
Anne G. Semb, MD, PhD*,
Sanne van Wissen, MD ,
Thor Ueland, BS ,
Tineke Smilde, MD, PhD,
Torgun Waehre, MD,
Mieke D. Tripp, MD, PhD ,
Stig S. Frøland, MD, PhD||,
John J. P. Kastelein, MD, PhD,
Lars Gullestad, MD, PhD¶,
Terje R. Pedersen, MD, PhD*,
P.ål Aukrust, MD, PhD||,* and
Anton F. H. Stalenhoef, MD, PhD
* Cardiologic Department, Aker Hospital, Oslo, Norway
Research Institute for Internal Medicine, Oslo, Norway
|| Section of Clinical Immunology and Infectious Diseases, Rikshospitalet, Oslo, Norway
¶ Medical Department, Baerum Hospital, Baerum, Norway
Academic Medical Center, Amsterdam, The Netherlands
Department of Medicine, University Medical Center, Nijmegen, The Netherlands
Manuscript received April 29, 2002;
revised manuscript received September 20, 2002,
accepted October 4, 2002.
* Reprint requests and correspondence: Dr. Pål Aukrust, Section of Clinical Immunology and Infectious Diseases, Medical Department, Rikshospitalet, N-0027 Oslo, Norway.
pal.aukrust{at}rikshospitalet.no
OBJECTIVES: In the present study, we investigated the effects of statins on serum levels of soluble CD40 ligand (sCD40L) in patients with familial hypercholesterolemia (FH).
BACKGROUND: Atherosclerotic disease seems to involve inflammatory and immunologic mechanisms, and sCD40L has recently been identified as one of the key players in the atherosclerotic process. HMG-Co A reductase inhibitors, statins, have been recognized as immunomodulators and reduce cardiovascular events and mortality, but the effects of statins on sCD40L has not been clarified.
METHODS: In a randomized, double-blind, clinical trial, as part of the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) trial, 110 patients with FH were given atorvastatin 80 mg/daily (n = 57) or simvastatin 40 mg/daily (n = 53) for two years.
RESULTS: Our main findings were: 1) at baseline patients with FH had significantly higher (approximately 27-fold) serum levels of sCD40L than healthy controls; 2) statin therapy markedly decreased serum levels of sCD40L (approximately 40% reduction); 3) this decrease in sCD40L was found during both "aggressive" (i.e., atorvastatin) and "conventional" (i.e., simvastatin) statin therapy and was not correlated with the degree of reduction in cholesterol levels.
CONCLUSIONS: Our findings may suggest enhanced CD40L-CD40 interaction in FH and that this inflammatory response may be downregulated by statins.
|
Abbreviations and Acronyms
| | CVD | | cardiovascular disease | | EIA | | enzyme immunoassay | | FH | | familial hypercholesterolemia | | hsCRP | | high-sensitivity C-reactive protein | | IMT | | intima media thickness | | LDL | | low-density lipoprotein | | LDL-C | | LDL cholesterol | | sCD40L | | soluble CD40 ligand |
|
This article has been cited by other articles:
|
|
|
|
 
K. Y. Stokes, L. Calahan, C. M. Hamric, J. M. Russell, and D. N. Granger
CD40/CD40L contributes to hypercholesterolemia-induced microvascular inflammation
Am J Physiol Heart Circ Physiol,
March 1, 2009;
296(3):
H689 - H697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Chen, H. Chai, X. Wang, J. Jiang, M. S. Jamaluddin, D. Liao, Y. Zhang, H. Wang, U. Bharadwaj, S. Zhang, et al.
Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells
Blood,
October 15, 2008;
112(8):
3205 - 3216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Isma, J. Barani, I. Mattiasson, B. Lindblad, and A. Gottsater
Lipid-Lowering Therapy is Related to Inflammatory Markers and 3-Year Mortality in Patients With Critical Limb Ischemia
Angiology,
October 1, 2008;
59(5):
542 - 548.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Natal, P. Restituto, C. Inigo, I. Colina, J. Diez, and N. Varo
The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin
J. Clin. Endocrinol. Metab.,
June 1, 2008;
93(6):
2319 - 2327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello
Role of Inflammation in Atherosclerosis
J. Nucl. Med.,
November 1, 2007;
48(11):
1800 - 1815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Hocher, L. Liefeldt, T. Quaschning, P. Kalk, R. Ziebig, M. Godes, K. Relle, G. Asmus, and J.-P. Stasch
Soluble CD154 Is a Unique Predictor of Nonfatal and Fatal Atherothrombotic Events in Patients Who Have End-Stage Renal Disease and Are on Hemodialysis
J. Am. Soc. Nephrol.,
April 1, 2007;
18(4):
1323 - 1330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Anwaruddin, A. T. Askari, and E. J. Topol
Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine
J. Am. Coll. Cardiol.,
January 23, 2007;
49(3):
279 - 289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. K. Koh, S. H. Han, and M. J. Quon
Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions
J. Am. Coll. Cardiol.,
December 6, 2005;
46(11):
1978 - 1985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. de Lemos, A. Zirlik, U. Schonbeck, N. Varo, S. A. Murphy, A. Khera, D. K. McGuire, G. Stanek, H. S. Lo, R. Nuzzo, et al.
Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2005;
25(10):
2192 - 2196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ueland, P. Aukrust, A. Yndestad, K. Otterdal, S. S. Froland, K. Dickstein, J. Kjekshus, L. Gullestad, and J. K. Damas
Soluble CD40 ligand in acute and chronic heart failure
Eur. Heart J.,
June 1, 2005;
26(11):
1101 - 1107.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Steiner, W. S. Speidl, J. Pleiner, D. Seidinger, G. Zorn, C. Kaun, J. Wojta, K. Huber, E. Minar, M. Wolzt, et al.
Simvastatin Blunts Endotoxin-Induced Tissue Factor In Vivo
Circulation,
April 12, 2005;
111(14):
1841 - 1846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E C Jury and M R Ehrenstein
Statins: immunomodulators for autoimmune rheumatic disease?
Lupus,
March 1, 2005;
14(3):
192 - 196.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Sanguigni, P. Pignatelli, L. Lenti, D. Ferro, A. Bellia, R. Carnevale, M. Tesauro, R. Sorge, R. Lauro, and F. Violi
Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients
Circulation,
February 1, 2005;
111(4):
412 - 419.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tunon, L. M. Blanco-Colio, J. L. Martin-Ventura, and J. Egido
Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?
Nephrol. Dial. Transplant.,
November 1, 2004;
19(11):
2696 - 2699.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Li, S.-P. Zhao, D.-q. Peng, Z.-m. Xu, and H.-n. Zhou
Early Effect of Pravastatin on Serum Soluble CD40L, Matrix Metalloproteinase-9, and C-Reactive Protein in Patients with Acute Myocardial Infarction
Clin. Chem.,
September 1, 2004;
50(9):
1696 - 1699.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Vishnevetsky, V. A Kiyanista, and P. J Gandhi
CD40 Ligand: A Novel Target in the Fight Against Cardiovascular Disease
Ann. Pharmacother.,
September 1, 2004;
38(9):
1500 - 1508.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby, and for the Myocardial Ischemia Reduction with Aggress
Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study
Circulation,
July 27, 2004;
110(4):
386 - 391.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Schonbeck and P. Libby
Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents?
Circulation,
June 1, 2004;
109(21_suppl_1):
II-18 - II-26.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shimada, K. Miyauchi, H. Daida, S. Kinlay, P. Libby, P. Ganz, For the MIRACL Study Investigators, G. G. Schwartz, A. G. Olsson, N. Rifai, et al.
Early Intervention With Atorvastatin Modulates Th1/Th2 Imbalance in Patients With Acute Coronary Syndrome: From Bedside to Bench * Response
Circulation,
May 11, 2004;
109(18):
e213 - e214.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Granger, T. Vowinkel, and T. Petnehazy
Modulation of the Inflammatory Response in Cardiovascular Disease
Hypertension,
May 1, 2004;
43(5):
924 - 931.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.M Sacks
Do statins play a role in the early management of the acute coronary syndrome?
Eur. Heart J. Suppl.,
March 1, 2004;
6(suppl_A):
A32 - A36.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Lutgens, R.-J. van Suylen, B. C. Faber, M. J. Gijbels, P. M. Eurlings, A.-P. Bijnens, K. B. Cleutjens, S. Heeneman, and M. J.A.P. Daemen
Atherosclerotic Plaque Rupture: Local or Systemic Process?
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2003;
23(12):
2123 - 2130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Bereczki, E. Nagy, A. Pal, M. T. Magyar, J. Balla, G. J. Blake, R. J. Ostfeld, E. K. Yucel, N. Varo, U. Schonbeck, et al.
Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples? *
Arterioscler. Thromb. Vasc. Biol.,
June 12, 2003;
23(6):
1129 - 1130.
[Full Text]
[PDF]
|
|
|
|
